Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

953
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
953
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.4K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.4K
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

854
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
854
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives01:22

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

907
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
907
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

1.6K
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
1.6K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Direct inhibition of the TXNIP-NLRP3-GSDMD pathway reduces pyroptosis in colonocytes and alleviates ulcerative colitis in mice by the small compound PEITC.

Acta pharmacologica Sinica·2025
Same author

First Report of <i>Aspergillus flavus</i> Causing Root Rot on peony (<i>Paeonia suffruticosa</i>) in Tongling, China.

Plant disease·2025
Same author

[Clinical application of nerve block in early analgesia after anterior cruciate ligament reconstruction].

Zhongguo gu shang = China journal of orthopaedics and traumatology·2025
Same author

Promoting lignocellulosic biorefinery by machine learning: progress, perspectives and challenges.

Bioresource technology·2025
Same author

A Study of 3D Printing Technology in the Fabrication and Clinical Application of Titanium Mesh Shaping Molds for Cranial Bone Repairs.

The Journal of craniofacial surgery·2025
Same author

Nf2-FAK signaling axis is critical for cranial bone ossification and regeneration.

Nature communications·2025

Related Experiment Video

Updated: May 2, 2026

Comparative Study on the Polysaccharide Contents and Antioxidant Activities of Hippophae rhamnoides subsp. sinensis and Hippophae gyantsensis
10:03

Comparative Study on the Polysaccharide Contents and Antioxidant Activities of Hippophae rhamnoides subsp. sinensis and Hippophae gyantsensis

Published on: August 15, 2025

868

Konjac glucomannan, a promising polysaccharide for OCDDS.

Cui Zhang1, Ji-da Chen1, Feng-Qing Yang1

  • 1School of Chemistry and Chemical Engineering, ChongQing University, ChongQing 400030, People's Republic of China.

Carbohydrate Polymers
|March 11, 2014
PubMed
Summary

Konjac glucomannan (KGM) shows promise as a natural excipient for oral colon targeting drug delivery systems (OCDDS). Its unique properties enable targeted drug release in the colon, offering a novel approach for treating colonic diseases.

Keywords:
Colon targetingExcipientKonjac glucomannan

More Related Videos

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

741
Isolation and Purification of Fungal &#946;-Glucan as an Immunotherapy Strategy for Glioblastoma
10:02

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma

Published on: June 2, 2023

2.8K

Related Experiment Videos

Last Updated: May 2, 2026

Comparative Study on the Polysaccharide Contents and Antioxidant Activities of Hippophae rhamnoides subsp. sinensis and Hippophae gyantsensis
10:03

Comparative Study on the Polysaccharide Contents and Antioxidant Activities of Hippophae rhamnoides subsp. sinensis and Hippophae gyantsensis

Published on: August 15, 2025

868
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

741
Isolation and Purification of Fungal &#946;-Glucan as an Immunotherapy Strategy for Glioblastoma
10:02

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma

Published on: June 2, 2023

2.8K

Area of Science:

  • Pharmacology and Pharmaceutical Sciences
  • Biomaterials Science
  • Natural Product Chemistry

Background:

  • Oral colon targeting drug delivery systems (OCDDS) are crucial for localized colonic disease treatment and drug absorption.
  • Utilizing colon-specific enzyme degradation of excipients is a leading strategy for achieving colon targeting.
  • Konjac glucomannan (KGM) possesses advantageous properties for OCDDS, including specific degradation by colon enzymes, biocompatibility, and stability.

Purpose of the Study:

  • To review the structure and properties of konjac glucomannan (KGM).
  • To summarize recent advancements and future prospects of KGM and its modified forms as pharmaceutical excipients for oral colon targeting drug delivery systems (OCDDS).

Main Methods:

  • Literature review focusing on konjac glucomannan (KGM) and its application in oral colon targeting drug delivery systems (OCDDS).
  • Analysis of KGM's properties, including its degradation by colon enzymes (e.g., β-mannanase), biocompatibility, gel-forming capacity, low toxicity, and stability.
  • Evaluation of modified KGM derivatives for enhanced performance in OCDDS.

Main Results:

  • Konjac glucomannan (KGM) exhibits specific degradation by colon β-mannanase, making it suitable for colon-specific drug release.
  • KGM demonstrates excellent biocompatibility, gel-forming ability, low toxicity, and high stability, key attributes for pharmaceutical excipients.
  • Both native and modified KGM show significant potential for developing effective oral colon targeting drug delivery systems (OCDDS).

Conclusions:

  • Konjac glucomannan (KGM) is a highly promising natural excipient for oral colon targeting drug delivery systems (OCDDS) due to its unique enzymatic degradation profile and favorable physicochemical properties.
  • Further research into modified konjac glucomannan (KGM) derivatives is expected to enhance its utility and expand applications in targeted colon therapy.
  • KGM-based formulations offer a viable and effective strategy for treating colonic diseases and improving drug delivery to the colon.